 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2772 News |  |
| «12...27282930313233343536373839» |
- || Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Tremfya (guselkumab) / J&J
How much is tremfya and skyrizi? Prices coming down? (Twitter) - Oct 16, 2019
- | Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, P3 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. (Pubmed Central) - Oct 15, 2019
P3
Guselkumab showed superior long-term efficacy based on PASI 90 at week 48 when compared with secukinumab for treating moderate-to-severe psoriasis. This finding could assist health-care providers in their decision making process when selecting a biologic for treating moderate-to-severe psoriasis.
- ||||| Tremfya (guselkumab) / J&J
Clinical, P3 data: I will never say no to another tool in the old toolbox. 0807 Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, RCT (Twitter) - Oct 12, 2019
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Oct 9, 2019
P=N/A, N=107, Active, not recruiting, Sponsor: University of California, San Diego
This finding could assist health-care providers in their decision making process when selecting a biologic for treating moderate-to-severe psoriasis. Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Jul 2022 | Trial primary completion date: Nov 2018 --> Nov 2020
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2575;
These findings were consistent with those for the overall study population of patients with plaque PsO. AEs observed were generally consistent with the established safety profiles for GUS and SEC.
- Tremfya (guselkumab) / J&J
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study (Hall B1) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1780;
In pts with active PsA who were biologic-naïve or had been treated with TNFi, both GUS Q4W and Q8W demonstrated efficacy for joint and skin symptoms, physical function, and quality of life relative to PBO. Observed AEs were consistent with GUS safety established in PsO.
- | Tremfya (guselkumab) / J&J
Enrollment open, Trial completion date: QUASAR: A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Oct 6, 2019
P2b, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Observed AEs were consistent with GUS safety established in PsO. Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Sep 2025
- | Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J, Xeljanz (tofacitinib) / Pfizer
Review, Journal: Emerging treatment options for spondyloarthritis. (Pubmed Central) - Oct 4, 2019
IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab are further emerging drugs for PsA. Thus, the number of treatment options in SpA is likely to be increased over the next few years that make identification of optimal treatment strategies essential.
- | Tremfya (guselkumab) / J&J
Journal: Treatment of Pityriasis Rubra Pilaris With Guselkumab. (Pubmed Central) - Oct 3, 2019
Thus, the number of treatment options in SpA is likely to be increased over the next few years that make identification of optimal treatment strategies essential. No abstract available
- | Tremfya (guselkumab) / J&J
Clinical, Journal: A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. (Pubmed Central) - Sep 28, 2019
The relative merits of longitudinal and landmark analysis also are discussed. The results provide a comprehensive and robust evaluation of the D-R relationship.
- | Tremfya (guselkumab) / J&J
Enrollment open: G-PLUS: A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (clinicaltrials.gov) - Sep 23, 2019
P3b, N=105, Recruiting, Sponsor: Janssen-Cilag Ltd.
The results provide a comprehensive and robust evaluation of the D-R relationship. Not yet recruiting --> Recruiting
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
P2 data, P3 data, Journal: Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. (Pubmed Central) - Sep 11, 2019
Guselkumab appears to be a safe and effective option for the treatment of moderate-to-severe plaque psoriasis in patients who have been screened for susceptibility to infection and are candidates for systemic treatment or phototherapy. However, long-term safety data are lacking.
- | Tremfya (guselkumab) / J&J
Biomarker, New P1 trial: Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. (clinicaltrials.gov) - Sep 9, 2019
P1, N=10, Not yet recruiting, Sponsor: Rockefeller University
- | Tremfya (guselkumab) / J&J
New P4 trial: BIOLOPTIM-GUS: Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (clinicaltrials.gov) - Sep 5, 2019
P4, N=100, Recruiting, Sponsor: University Ghent
- | Stelara (ustekinumab) / J&J, Xeljanz (tofacitinib) / Pfizer
Review, Journal: Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. (Pubmed Central) - Aug 27, 2019
Janus tyrosine kinase(JAK) inhibitors also directly affect IL-23 and, thus, IL-17. After the first-generation pan-JAK inhibitors have been shown efficacy (tofacitinib, baricitinib), new-generation selective JAK inhibitors (filgotinib, upadacitinib) are under investigation in psoriasis and PsA.
- | Dupixent (dupilumab) / Sanofi, Regeneron
Retrospective data, Journal, Combination therapy: A retrospective review of dupilumab and psoriasis biologic combination therapy. (Pubmed Central) - Aug 24, 2019
No serious adverse effects were observed. Although cost consideration and long-term monitoring to evaluate the true safety of biologic treatment used in combination are necessary, the benefits may outweigh the risks of using dupilumab with other biologics in combination in patients with these indications.
- | Tremfya (guselkumab) / J&J
New P2 trial: HiGUS: Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (clinicaltrials.gov) - Aug 19, 2019
P2, N=20, Not yet recruiting, Sponsor: Barbara Horv
- |||||| Taltz (ixekizumab) / Eli Lilly, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Adverse events: ECLIPSE RCT: guselkumab (IL23i) vs. secukinumab (IL17i) in @TheLancet @RheumNow PASI90 84% for GUS vs 70% for SEK at wk 48, NNT ~7 favoring GUS Similar rate of adverse events Runs counter to Lilly announcement that ixekizumab (IL17i) was better than guselkumab in recent RCT (Twitter) - Aug 15, 2019
- ||||| Taltz (ixekizumab) / Eli Lilly, Tremfya (guselkumab) / J&J
Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK (Twitter) - Aug 14, 2019
- | Tremfya (guselkumab) / J&J
Review, Journal: Guselkumab for the treatment of psoriasis - evidence to date. (Pubmed Central) - Aug 9, 2019
They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.
- | Tremfya (guselkumab) / J&J
Enrollment closed: NOVA: A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (clinicaltrials.gov) - Aug 8, 2019
P2, N=184, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis. Recruiting --> Active, not recruiting
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment closed: IXORA-R: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 8, 2019
P4, N=960, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Journal: Risankizumab (Skyrizi) for psoriasis. (Pubmed Central) - Aug 6, 2019
Recruiting --> Active, not recruiting No abstract available
- | Tremfya (guselkumab) / J&J
Review, Journal: Guselkumab for plaque psoriasis. (Pubmed Central) - Aug 2, 2019
No abstract available No abstract available
- | Clinical, Review, Journal: Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. (Pubmed Central) - Jul 31, 2019
In this article, we review studies of psoriasis treatments and their level of evidence for use in co-occurring diseases. An awareness of the multifaceted effects of certain psoriasis medications can enable physicians to provide more personalized treatment to their most complicated patients.
- | Tremfya (guselkumab) / J&J
New P2b trial: QUASAR: A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Jul 25, 2019
P2b, N=1000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Journal: Safinamide mesylate, Brodalumab, Guselkumab, and Abaloparatide. (Pubmed Central) - Jul 24, 2019
An awareness of the multifaceted effects of certain psoriasis medications can enable physicians to provide more personalized treatment to their most complicated patients. No abstract available
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
New P1 trial: Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants (clinicaltrials.gov) - Jul 23, 2019
P1, N=60, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Review, Journal: Therapeutic drug monitoring of biologics in psoriasis. (Pubmed Central) - Jul 18, 2019
We also propose a treatment algorithm for the practical application of TDM depending on drug trough concentrations, presence/absence of anti-drug antibodies and clinical response of patients. The practice of TDM is recommended in routine clinical practice where possible.
- Tremfya (guselkumab) / J&J
Long-term Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis: Integrated Data Through Week 156 of the Phase 3 VOYAGE 1 and VOYAGE 2 Trials (N109-110) - Jul 16, 2019 - Abstract #EADV2019EADV_3137;
- Tremfya (guselkumab) / J&J
Consistent Response to Guselkumab by Disease Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial (N109-110) - Jul 16, 2019 - Abstract #EADV2019EADV_3131;
- Tremfya (guselkumab) / J&J
Guselkumab in the treatment of patients affected by moderate- severe plaque psoriasis: real-word evidence (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2804;
- Tremfya (guselkumab) / J&J
Consistent Responses to Guselkumab by Geographic Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2747;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Absolute Psoriasis Area and Severity Index Improvement in Psoriasis Patients Treated With Guselkumab or Secukinumab: Results From the ECLIPSE Study (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2732;
- Tremfya (guselkumab) / J&J
Pharmacokinetics and Immunogenicity of Guselkumab Through up to 3 Years of Therapy in Patients With Moderate-to-Severe Plaque Psoriasis (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2706;
- Tremfya (guselkumab) / J&J
Guselkumab is superior compared to fumaric acid esters in improving the quality of life of systemic naive and FAE pre-treated psoriasis patients - week 56 results from the POLARIS trial (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2695;
- Tremfya (guselkumab) / J&J
The 64-week safety profile of guselkumab is favorable compared to fumaric acid esters in psoriasis patients - long term safety results from the German POLARIS trial (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2694;
- Tremfya (guselkumab) / J&J
Guselkumab is the favorable initial treatment option in patients with moderate-to-severe plaque psoriasis naive to systemic treatment and is also effective after switch from FAE to guselkumab (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2693;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Efficacy of Guselkumab Versus Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis in Subgroups Defined by Previous Psoriasis Medication History: Results From the ECLIPSE Study (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2692;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Consistency of Response by Disease Severity Characteristics in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From ECLIPSE Study (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2691;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Guselkumab Demonstrates Greater Efficacy Compared to Secukinumab Across Body Weight Quartiles and Body Mass Index Categories: Week 48 Results From the ECLIPSE Trial (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2688;
- Tremfya (guselkumab) / J&J
Efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis in real-world clinical practice (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2672;
- Tremfya (guselkumab) / J&J
Demographics and disease characteristics of patients with psoriasis who initiated guselkumab in a large North American psoriasis registry (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2660;
- Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Consistency of Response by age in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From the ECLIPSE Study Trial (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2659;
- Tremfya (guselkumab) / J&J
Patient reported outcomes among patients with psoriasis who initiated guselkumab in a large North American psoriasis registry (e-Poster Hall) - Jul 16, 2019 - Abstract #EADV2019EADV_2657;
- | Tremfya (guselkumab) / J&J
Journal: Tremfya™ (Guselkumab). (Pubmed Central) - Jul 11, 2019
The practice of TDM is recommended in routine clinical practice where possible. No abstract available
- | Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial. (Pubmed Central) - Jul 4, 2019
P3
Targeting interleukin 23 with guselkumab may be an effective and safe treatment option for a recalcitrant disease such as PPP. ClinicalTrials.gov identifier: NCT02641730.
- | Review, Journal: Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. (Pubmed Central) - Jul 4, 2019
Under the regulation of IL-23, T cells that produce high levels of IL-17 create a self-amplifying, feed-forward inflammatory response in keratinocytes that drives the development of thickened skin lesions infiltrated with a mixture of inflammatory cell populations. Recently, the Food and Drug Administration approved multiple highly effective psoriasis therapies that disrupt IL-17 (secukinumab, ixekizumab, and brodalumab) and IL-23 (guselkumab and tildrakizumab) signaling in the skin, thus leading to a major paradigm shift in the way that psoriatic disease is managed.
- |||||||| Tremfya (guselkumab) / J&J
New P3 trial: G-PLUS: A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (clinicaltrials.gov) - Jun 25, 2019
P3b, N=105, Not yet recruiting, Sponsor: Janssen-Cilag Ltd.